

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: David WALLACH et al

Art Unit: 1642

Application No. 09/445,223

Conf. No.: 966-

Examiner: M. Davis

Filed: December 6, 1999

Washington, D.C.

For: MODULATORS OF INTRACELLULAR INFLAMMATION, CELL DEATH AND ...

Atty.'s Docket: WALLACH=24

Date: August 22, 2002

RECEIVED
AUG 26 2002
TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231



Sir:

Transmitted herewith is a Amendment. _____
 in the above-identified application.

Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 25	MINUS	** 39		0
INDEP.	* 1	MINUS	*** 3		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL \$	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
OR TOTAL \$	

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity	
Response Filed Within	
<input type="checkbox"/> First	- \$ 55.00
<input type="checkbox"/> Second	- \$ 200.00
<input type="checkbox"/> Third	- \$ 460.00
<input type="checkbox"/> Fourth	- \$ 720.00
Month After Time Period Set	

Other Than Small Entity	
Response Filed Within	
<input type="checkbox"/> First	- \$ 110.00
<input type="checkbox"/> Second	- \$ 400.00
<input type="checkbox"/> Third	- \$ 920.00
<input type="checkbox"/> Fourth	- \$ 1440.00
Month After Time Period Set	

Less fees (\$ _____) already paid for _____ month(s) extension of time on _____.

Please charge my Deposit Account No. 02-4035 in the amount of \$ _____.

Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ _____.

A check in the amount of \$ _____ is attached (check no.).

The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By:
 Roger L. Browdy
 Registration No. 25,618

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#13/E
Jm
8/27/02

TECH CENTER 1600/2900

AUG 26 2002

RECEIVED

Atty. Docket: WALLACH=24

In re Application of:)	Conf. No. 9660
David WALLACH)	Art Unit: 1642
Appln. No.: 09/445,223)	Examiner: M. Davis
Filed: December 6, 1999)	Washington, D.C.
For: MODULATORS OF)	August 22, 2002
INTRACELLULAR INFLAMMATION))	
CELL DEATH, AND ...)	

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of May 22, 2002,
please amend as follows:

IN THE CLAIMS

Delete claims 12, 16, 17, 19, 31-37 and 50 without
prejudice toward the continuation of prosecution thereof in
divisional applications.

Please amend claims 23, 24, 40, 44-47 and 51 as
follows:

23 (Thrice-amended). A composition comprising a
pharmaceutically acceptable excipient and a recombinant animal
virus vector comprising a DNA sequence according to claim 44.

E1

Sub 71
24 (Thrice-amended). A composition comprising a
pharmaceutically acceptable excipient and an oligonucleotide
molecule consisting of a sequence encoding an antisense
sequence of at least part of an mRNA sequence corresponding to
a DNA sequence according to claim 44.